InMed Pharmaceuticals (INM) Shares Outstanding (Diluted Average) (2019 - 2026)
InMed Pharmaceuticals (INM) reported Shares Outstanding (Diluted Average) of $4.0 million for Q1 2026, up 395.74% on a YoY basis from $803909.0 in Q1 2025, and up 0.78% quarter-over-quarter from $4.0 million in Q4 2025.
InMed Pharmaceuticals (INM) Shares Outstanding (Diluted Average) (2019 - 2026) Analysis & Trends
InMed Pharmaceuticals has reported Shares Outstanding (Diluted Average) for 8 years, with the latest figure at $4.0 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 395.74% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (up 395.74% YoY), and the FY2025 full-year result was $975985.0, up 156.13% from the prior year.
- Shares Outstanding (Diluted Average) for Q1 2026 stood at $4.0 million, up from $4.0 million in the prior quarter.
- The five-year high for Shares Outstanding (Diluted Average) was $4.0 million in Q1 2026, with the low at $166410.0 in Q3 2023.
- Historically, Shares Outstanding (Diluted Average) has averaged $1.5 million across 5 years, with a median of $661052.0 in 2024.
- Annual changes were most pronounced in 2024 — Shares Outstanding (Diluted Average) plunged 84.44% — and 2025, when it soared 537.7%.
- InMed Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $533070.0 in 2022, then sank by 47.0% to $282541.0 in 2023, then soared by 133.97% to $661052.0 in 2024, then soared by 498.22% to $4.0 million in 2025, then advanced by 0.78% to $4.0 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $4.0 million (Q1 2026), $4.0 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 1.18 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 422.40 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 47.20 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 103.40 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 506.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | - |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 228.36 Mn |
| 10 | InMed Pharmaceuticals | 6.00 Mn | 756,271.05 | - | 3.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.99 Mn |
| Dec 31, 2025 | 3.95 Mn |
| Sep 30, 2025 | 3.95 Mn |
| Jun 30, 2025 | 975,985.00 |
| Mar 31, 2025 | 803,909.00 |
| Dec 31, 2024 | 661,052.00 |
| Sep 30, 2024 | 620,127.00 |
| Jun 30, 2024 | 381,053.00 |
| Mar 31, 2024 | 348,097.00 |
| Dec 31, 2023 | 282,541.00 |
| Sep 30, 2023 | 166,410.00 |
| Jun 30, 2023 | 2.45 Mn |
| Mar 31, 2022 | 533,070.00 |
| Jun 30, 2021 | 268,793.00 |
| Jun 30, 2020 | 5.22 Mn |
| Mar 31, 2020 | 5.22 Mn |
| Dec 31, 2019 | 5.22 Mn |
| Sep 30, 2019 | 5.22 Mn |